Business Description
ISIN : US0044685008
Total Employee Number:
28Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.53 | |||||
Equity-to-Asset | -0.08 | |||||
Debt-to-Equity | -1.02 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 31.4 | |||||
3-Year EPS without NRI Growth Rate | 32.3 | |||||
3-Year FCF Growth Rate | 31.6 | |||||
3-Year Book Growth Rate | -4.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.96 | |||||
9-Day RSI | 72.49 | |||||
14-Day RSI | 70.95 | |||||
3-1 Month Momentum % | 33.77 | |||||
6-1 Month Momentum % | 28.96 | |||||
12-1 Month Momentum % | 95.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.95 | |||||
Quick Ratio | 0.95 | |||||
Cash Ratio | 0.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -43.8 | |||||
Shareholder Yield % | -0.44 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -614.42 | |||||
ROA % | -151.52 | |||||
ROIC % | -126.89 | |||||
3-Year ROIIC % | 124.56 | |||||
ROC (Joel Greenblatt) % | -177188.09 | |||||
ROCE % | -405.37 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -6.01 | |||||
EV-to-EBITDA | -6.02 | |||||
EV-to-Forward-Revenue | 14.3 | |||||
EV-to-FCF | -14.46 | |||||
Earnings Yield (Greenblatt) % | -16.64 | |||||
FCF Yield % | -5.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACHV
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Achieve Life Sciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.55 | ||
| Beta | 2.8543 | ||
| 3-Year Sharpe Ratio | 0.35 | ||
| 3-Year Sortino Ratio | 0.63 | ||
| Volatility % | 92.24 | ||
| 14-Day RSI | 70.95 | ||
| 14-Day ATR ($) | 0.417126 | ||
| 20-Day SMA ($) | 7.21525 | ||
| 12-1 Month Momentum % | 95.51 | ||
| 52-Week Range ($) | 2.62 - 8.61 | ||
| Shares Outstanding (Mil) | 102.9 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Achieve Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Achieve Life Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 72 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 71 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-21 08:30 | 8.02 (-4.75%) | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 6.67 (+0.15%) | ||
| General meeting for 2026 | 2026-07-02 09:00 | 6.40 (-1.39%) | ||
| Annual report for 2025 | 2026-06-08 | 5.13 (-1.91%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:30 | 5.59 (+8.33%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 5.59 (+8.33%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-24 08:30 | 4.05 (-1.22%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 4.05 (-1.22%) |
Achieve Life Sciences Inc Frequently Asked Questions
Guru Commentaries on NAS:ACHV
Achieve Life Sciences, Inc has shown promising long-term trial results with zero safety concerns, which positions it well in the market. Despite the frustrating performance drag, the current valuation is described as 'ludicrous,' indicating significant upside potential. The company is expected to file for NDA in June, with anticipated positive results in July that could lead to a substantial rise in stock price. The manager believes that Achieve Life Sciences, Inc could be an obvious take-out target if the upcoming results are favorable, projecting a potential 5x-8x upside from current levels.
Achieve Life Sciences, Inc has shown promising long-term trial results with zero safety concerns, which positions it well in the market. Despite the frustrating performance drag, the current valuation is described as 'ludicrous,' indicating significant upside potential. The company is expected to file for NDA in June, with positive July results anticipated. The manager believes that if the results are favorable, Achieve Life Sciences, Inc could become an obvious take-out target, with an expected upside of 5x-8x from current levels.
Press Release
Articles on Achieve Life Sciences Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
